Natural Product (NP) Details

General Information of the NP (ID: NP3975)
Name
Cilostazol
Synonyms
cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; OPC-13013; Cilostazolum; Cilostazolum [INN-Latin]; OPC 13013; OPC 21; OPC-21; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; UNII-N7Z035406B; CHEBI:31401; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one; MLS000028470; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; MFCD00866780; N7Z035406B; NCGC00015207-07; SMR000058428; 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one; DSSTox_CID_25132; DSSTox_RID_80693; DSSTox_GSID_45132; CAS-73963-72-1; Pletal (TN); SR-01000003107; BRN 3632107; Cilostazol,(S); Cilostazol [USAN:USP:INN:BAN:JAN]; Tocris-1692; Opera_ID_488; Spectrum2_001118; Spectrum3_001170; Spectrum4_000772; Spectrum5_001762; Lopac-C-0737; CHEMBL799; C 0737; Lopac0_000218; REGID_for_CID_2754; SCHEMBL16128; BSPBio_002759; KBioGR_001184; MLS000758281; MLS000759507; MLS001076067; MLS002153891; SPECTRUM1505230; SPBio_001256; Cilostazol (JP17/USP/INN); GTPL7148; DTXSID9045132; HSDB 8312; KBio3_002259; BCPP000279; HMS1922N15; HMS2093M14; HMS2096F16; HMS2234C06; HMS3260L17; HMS3268O09; HMS3412B18; HMS3654J13; HMS3676B18; HMS3713F16; Pharmakon1600-01505230; ACT02663; BCP03724; ZINC1552174; Tox21_110098; Tox21_500218; BDBM50225508; CCG-39646; KM1582; NSC758936; s1294; AKOS015855512; Cilostazol, >=98% (HPLC), powder; OPC 13013; OPC 21; Pletaal; Tox21_110098_1; AC-4334; AM90304; BCP9000530; CS-1759; DB01166; KS-5154; LP00218; MCULE-8893820969; NSC 758936; NSC-758936; SDCCGSBI-0050206.P003; 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-; 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; NCGC00015207-01; NCGC00015207-02; NCGC00015207-03; NCGC00015207-04; NCGC00015207-05; NCGC00015207-06; NCGC00015207-08; NCGC00015207-09; NCGC00015207-10; NCGC00015207-11; NCGC00015207-12; NCGC00015207-25; NCGC00022153-02; NCGC00022153-04; NCGC00022153-05; NCGC00022153-06; NCGC00022153-07; NCGC00260903-01; AK111532; HY-17464; BCP0726000145; RETAL;PLETAL;OPC 21;PLETAAL;Cilostal; SBI-0050206.P002; AB0012441; EU-0100218; FT-0602474; FT-0645036; FT-0665038; SW199053-2; D01896; J90029; AB00382988-14; AB00382988_15; AB00382988_16; 963C721; A837982; Q258591; Q-200854; SR-01000003107-2; SR-01000003107-4; SR-01000003107-7; BRD-K67017579-001-04-2; BRD-K67017579-001-05-9; BRD-K67017579-001-07-5; BRD-K67017579-001-13-3; BRD-K67017579-001-17-4; SR-01000003107-10; Cilastatin sodium, Antibiotic for Culture Media Use Only; Cilostazol, United States Pharmacopeia (USP) Reference Standard; 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril; Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material; 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-; 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one; 89332-50-3
    Click to Show/Hide
Species Origin Broussonetia ...     Click to Show/Hide
Broussonetia
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Rosales
Family: Moraceae
Genus: Broussonetia
Disease Atherosclerosis [ICD-11: BD40] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C20H27N5O2
PubChem CID
2754
Canonical SMILES
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-N
CAS Number
CAS 73963-72-1
ChEBI ID
CHEBI:31401
TTD Drug ID
D03VPC
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Pravastatin      Hyper-lipoproteinaemia     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression ICAM1  Molecule Info 
Pathway MAP
                    In-vivo Model For a xenograft model, Ten-week-old LDLR KO mice were fed a high-fat, high cholesterol diet.
                    Experimental
                    Result(s)		 Combination therapy with pravastatin and cilostazol exerts beneficial effects by decreasing atherosclerotic lesion progression and improving the proinflammatory state in the vascular endothelium.
Target and Pathway
Target(s) Phosphodiesterase 3A (PDE3A)  Molecule Info  [3]
KEGG Pathway Purine metabolism Click to Show/Hide
2 cGMP-PKG signaling pathway
3 cAMP signaling pathway
4 Morphine addiction
Reactome cGMP effects Click to Show/Hide
2 G alpha (s) signalling events
WikiPathways miR-targeted genes in muscle cell - TarBase Click to Show/Hide
2 miR-targeted genes in lymphocytes - TarBase
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148).
Reference 2 Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice. Cardiovasc Ther. 2018 Dec;36(6):e12476.
Reference 3 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
 Download Picture         KEGG Link